Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

BMC cancer - 18 Jun 2012

Tengström Maria, Mannermaa Arto, Kosma Veli-Matti, Hirvonen Ari, Kataja Vesa

Abstract excerpt

BACKGROUND: Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). Homozygous SULT1A1 variant allele genotype has been associated with lower catalytic activity and thermostability of the en...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Arylsulfotransferase
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Finland

Share to Multivariate Analysis

Share to Survival Analysis

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 22708928
DOI: 10.1186/1471-2407-12-257
PMCID: PMC3388009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22708928-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?PMID 22708928Read ↗

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.Semantic proximity Read ↗

Sulfotransferase 1A2*2 is a risk factor for early-onset breast cancer.Semantic proximity Read ↗

Association between SULT1A1 Arg213His (rs9282861) Polymorphism and Risk of Breast Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.Semantic proximity Read ↗

Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.Semantic proximity Read ↗

MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.Semantic proximity Read ↗

Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival.Semantic proximity Read ↗

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.Semantic proximity Read ↗

A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.Semantic proximity Read ↗

Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.Semantic proximity Read ↗

OCA2 rs4778137 polymorphism predicts survival of breast cancer patients receiving neoadjuvant chemotherapy.Semantic proximity Read ↗

Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.